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Abstract
MRI-derived brain measures offer a link between genes, the environment and behav-
ior and have been widely studied in bipolar disorder (BD). However, many neuroimag-
ing studies of BD have been underpowered, leading to varied results and uncertainty
regarding effects. The Enhancing Neuro Imaging Genetics through Meta-Analysis
(ENIGMA) Bipolar Disorder Working Group was formed in 2012 to empower discov-
eries, generate consensus findings and inform future hypothesis-driven studies of
BD. Through this effort, over 150 researchers from 20 countries and 55 institutions
pool data and resources to produce the largest neuroimaging studies of BD ever con-
ducted. The ENIGMA Bipolar Disorder Working Group applies standardized
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processing and analysis techniques to empower large-scale meta- and mega-analyses
of multimodal brain MRI and improve the replicability of studies relating brain varia-
tion to clinical and genetic data. Initial BD Working Group studies reveal widespread
patterns of lower cortical thickness, subcortical volume and disrupted white matter
integrity associated with BD. Findings also include mapping brain alterations of com-
mon medications like lithium, symptom patterns and clinical risk profiles and have
provided further insights into the pathophysiological mechanisms of BD. Here we dis-
cuss key findings from the BD working group, its ongoing projects and future direc-
tions for large-scale, collaborative studies of mental illness.
K E YWORD S
bipolar disorder, cortical surface area, cortical thickness, ENIGMA, mega-analysis, meta-analysis,
MRI, neuroimaging, psychiatry, volume
1 | INTRODUCTION
1.1 | Overview
Bipolar disorder (BD) is a severe mental disorder characterized by epi-
sodic alterations in mood and activity levels including depression,
hypomania and mania. It is a leading cause of disability and affects
1% of the world's population (Merikangas et al., 2011; Vieta
et al., 2018). As a chronic illness, BD can lead to long-term functional
impairments and reduced quality of life for both patients and care-
givers (Oldis et al., 2016; Perlick, Rosenheck, Clarkin, Raue, &
Sirey, 2001; Vigo, Thornicroft, & Atun, 2016), which confer significant
societal costs (Ekman, Granstrom, Omerov, Jacob, & Landen, 2013).
Challenges remain in identifying robust and reproducible biomarkers
to better understand the neurobiology, nosology, diagnosis and
targeted treatments that are needed to improve patient outcomes in BD.
Mental health professionals continue to rely on a phenomenology-based
diagnostic system as opposed to validated biological markers1 to diag-
nose and treat BD. This is reflected in current diagnostic classification
systems, namely the DSM-5 (APA, 2013) and ICD-10 (WHO, 1993;
https://apps.who.int/iris/handle/10665/246208), which use the number
and profile of symptoms to delineate the unique and overlapping clinical
features of mental disorders, and allow individuals to be categorized
based on threshold criteria (BD diagnosis criteria provided in Supplemen-
tal Materials). While such approaches have improved the reliability of
diagnosing BD, misdiagnosis remains common, and hence biomarkers
such as those recently accepted for other disorders such as Alzheimer's
disease (Jack Jr. et al., 2018) are urgently needed for BD. To date, there
are still no valid biomarkers for the diagnosis of any mental disorder,
including BD (Quevedo & Yatham, 2018; Vieta et al., 2018; Vieta &
Phillips, 2007).
Non-invasive, in vivo measures of brain structure and function
derived from magnetic resonance imaging (MRI) have shed light on
the underlying brain alterations associated with BD. However, factors
such as clinical heterogeneity, high costs of data acquisition, variable
processing and analysis protocols, underpowered and generally cross-
sectional research designs, post analysis hypothesizing and publication
bias have resulted in variable findings and hindered the discovery of
validated biomarkers (Figure 1).
1.2 | Key challenges facing the use of
neuroimaging to study bipolar disorder
Neuroimaging has been used as a powerful, non-invasive tool to study
mental disorders such as BD for several decades, ever since early
studies revealing enlarged ventricles in patients with schizophrenia
(Johnstone, Crow, Frith, Husband, & Kreel, 1976). A key goal of
psychiatric neuroimaging research is to use MRI measures of brain
structure and function as a link between phenomenology, course, out-
come, treatment response, genetics and behavior. Unlike behavioral
outcome measures, MRI-derived brain measures have been proposed
to serve as an “endophenotype” – or a marker more closely related to
the underlying biology of a disorder. Such markers may have a simpler
genetic architecture or be more tractable to study compared to
behavioral phenotypes. There is mounting evidence that these in vivo
brain endophenotypes may help define the causal pathways between
heterogeneous behavioral alterations and genetic factors associated
with a given mental disorder (Bigos & Weinberger, 2010; Glahn,
Thompson, & Blangero, 2007; Gottesman & Shields, 1973, 1976; Hol-
land et al., 2020; Le & Stein, 2019).
A large body of both structural and functional neuroimaging
research has associated BD with abnormalities in the neural circuitry
of emotion and reward processing (Phillips & Swartz, 2014). Structural
studies have shown BD-related variation in cortical regions including
prefrontal, anterior temporal and insula cortices (Ganzola &
Duchesne, 2017; Hajek et al., 2013; Rimol et al., 2012) as well as
alterations in subcortical structures such as the hippocampus, thala-
mus and amygdala in individuals with BD compared to healthy con-
trols (HC) (Hajek et al., 2009; Hajek, Kopecek, Hoschl, & Alda, 2012;
Rimol et al., 2010). Studies of white matter in individuals with BD
using diffusion MRI (dMRI) have found disruptions in fronto-limbic
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white matter (WM) regions important to emotion regulation and
reward processing (Phillips & Swartz, 2014). Functional neuroimaging
studies have tied altered prefrontal, amygdala, temporal and ventral
striatum activity during emotion and reward tasks to BD (Phillips &
Swartz, 2014; Sepede et al., 2012, 2015, 2020).
However, while prior meta-analyses have found relative consen-
sus across studies (Ganzola & Duchesne, 2017), conflicting results are
not uncommon in neuroimaging studies of BD. For example, reports
of both larger and smaller structural volumes in participants with BD
versus HC are widely cited in the literature (Phillips & Swartz, 2014).
Such discrepancies can be traced to a core set of challenges facing
neuroimaging studies of BD (Figure 1; see Supplemental Materials for
further details on these challenges).
First, BD is a broad diagnostic category with varied clinical char-
acteristics likely including related underlying subtypes (i.e., biotypes
that subdivide or stratify conventional diagnostic categories). These
subtypes likely vary in underlying genetic and environmental risk,
treatment response, psychiatric/medical comorbidity, clinical course,
prognosis and pathophysiology (Duffy, Vandeleur, Heffer, & Preisig,
2017). Even the most carefully designed studies of BD will likely
include participant heterogeneity, as we do not fully understand the
underlying neurobiological stratification. We discuss the challenges of
linking current categorical diagnostic constructs of BD to underlying
biological measures in the Supplemental Materials. Study participant
heterogeneity in key variables affecting brain measures (e.g., diagnos-
tic method, age at scan, age of onset, illness duration, medication
status, etc.) adds noise to the already complicated task of detecting
the subtle effects of the disorder on MRI-derived brain metrics.
Second, the high cost of MRI data collection can restrict study sample
sizes (most studies collect data from fewer than 100 participants),
which may limit the statistical power to detect neurobiological effects
or model complex factors modulating BD symptoms. Third, variable
processing and analysis techniques for MRI make results hard to com-
pare across studies (Botvinik-Nezer et al., 2020). The power of tradi-
tional literature-based meta-analyses in BD neuroimaging studies is
somewhat limited by a lack of such standardized techniques (see the
following section for more detail). Fourth, most research studies are
cross-sectional, which limits analyses to static brain traits as opposed
to potential brain alterations over the course of illness in BD. Fifth,
underpowered and heterogeneous study samples may yield false posi-
tives or overestimate effects – a situation known as the “winner's
curse” (Button et al., 2013). Lastly, many studies suffer from post anal-
ysis hypothesizing or publication bias. All these challenges degrade
the reliability of findings, mandating the design of more replicable and
generalizable studies.
Under current diagnostic criteria, BD patient heterogeneity
(Charney et al., 2017; Stahl et al., 2019; Wolfers et al., 2018) can
affect study power depending on sample size (Button et al., 2013). In
smaller samples, patient heterogeneity can dilute the overall effect of
interest, either making it harder to detect subtle BD alterations or
overestimating true BD effects. In larger consortium studies with
increased statistical power, patient heterogeneity can lead to a more
“ecologically valid” sample that represents a larger fraction of the
patient space. While this heterogeneity in large samples can lead to
more replicable findings that apply more widely to BD in the general
population, subtle biological effects relevant to particular patient
F IGURE 1 Major challenges facing neuroimaging studies of BD and how the ENIGMA BDWorking Group meets these challenges
6 CHING ET AL.
subgroups may be obscured, requiring data-driven, post-hoc stratifica-
tion. Smaller, well-controlled studies that are able to implement
deeper phenotyping and novel analysis methods may be equipped to
isolate the underlying pathophysiology associated with particular
patient subgroups or symptom profiles, as long as the sample sizes are
still adequately powered to detect the effects.
Current structural and functional neuroimaging measures may
only account for a limited proportion of the overall variance in a com-
plex phenotypic trait such as BD diagnosis (Paulus & Thompson,
2019). Larger research samples may overcome the power limitations
of smaller studies and improve sensitivity to subtle brain signatures
(Westlye, Alnaes, van der Meer, Kaufmann, & Andreassen, 2019).
They may also offer a greater opportunity to model factors that
contribute to complex phenotypes such as BD. For example, some
medications commonly used to treat BD have shown morphometric
effects on MRI-derived brain metrics (Abe et al., 2015; Abramovic
et al., 2016; Hajek et al., 2014; Haukvik et al., 2020; Lyoo et al., 2010;
Moore et al., 2009; Moore, Bebchuk, Wilds, Chen, & Manji, 2000;
Sarrazin et al., 2019), including gray matter increases with lithium and
atrophic effects of anticonvulsants (Hibar et al., 2018). These
medication-related brain changes may be critical in the treatment of
BD, but they may also make brain alterations in the disorder harder to
detect, as most are highly confounded with illness status or severity.
The modeling of complex factors, such as medication history, can be
greatly improved in larger, pooled study samples.
These core challenges have contributed to the “replication crisis”
affecting much of biomedical research (Button et al., 2013; Dumas-
Mallet, Button, Boraud, Gonon, & Munafo, 2017; Ioannidis, 2008,
2011, 2017). To address these challenges, and to contribute to a
recent shift in psychiatry toward large consortium efforts, the
ENIGMA Bipolar Disorder Working Group was formed to pool data,
expertise and computational resources to discover factors that reliably
affect brain structure and function in BD.
Importantly, clinical symptoms (either categorical or dimensional)
remain the most useful metrics available to clinicians treating patients
with BD. While some of the research tools presented in this article
may one day improve BD care, these tools and methods must be rig-
orously validated and standardized if they are ever to be truly useful
in a clinical setting. In the following sections, we discuss how large-
scale efforts provide a path forward, and serve as an example of the
power of team science in pooling existing data and expertise to tackle
the core challenges facing BD research and treatment.
1.3 | The ENIGMA consortium: Large-scale,
collaborative studies of brain structure and function
An increasing number of common variants throughout the human
genome have been associated with risk for BD. The Psychiatric Geno-
mics Consortium (PGC) spearheaded a global effort to discover these
risk loci by coordinating large-scale psychiatric genetics studies
(https://www.med.unc.edu/pgc/). Many early genetic studies prior to
the PGC found associations between polymorphisms in candidate
genes and brain measures that later failed to replicate in larger indepen-
dent samples (Farrell et al., 2015). Genome-wide analyses have now
revealed hundreds of common genetic variants that are reliably associ-
ated with psychiatric disorders (Bipolar Disorder and Schizophrenia
Working Group of the Psychiatric Genomics Consortium, 2018;
Schizophrenia Working Group of the Psychiatric Genomics Consortium,
2014; Stahl et al., 2019; Wray et al., 2018), as well as discovered signifi-
cant genetic overlap between major disorders (Brainstorm et al., 2018;
Gandal et al., 2018).
As the PGC has done for genetics, large-scale, collaborative neu-
roimaging studies offer the power to answer new questions and
address prior inconsistencies in the literature. The ENIGMA Consor-
tium, launched in 2009, aimed to identify genetic variants that are
consistently associated with brain structure and function by per-
forming genome-wide association studies (GWAS) on measures from
brain MRI. To overcome the statistical power limitations of GWAS
(as most genetic polymorphisms associated with brain measures
account for less than 1% of the overall variance in any given brain
measure), the initial ENIGMA projects recruited samples with both
MRI and genetic data and implemented standardized processing and
analysis methods. These protocols enabled highly powered, prospec-
tive meta-analyses on a scale not previously possible (i.e., 99% power
to detect genetic loci explaining at least 1% of the variance in a given
brain trait). These initial studies identified new genetic variants associ-
ated with variability in brain volumes such as the hippocampus (Hibar
et al., 2015; Stein et al., 2012). More recently, collaborations between
ENIGMA and other large-scale international consortia, such as
CHARGE, were able to replicate initial findings in larger independent
samples and provided new insights into the genetic mechanisms
influencing brain structure (Adams et al., 2016; Grasby et al., 2020;
Hibar et al., 2017; Satizabal et al., 2019), function (Smit et al., 2018),
and development (Brouwer et al., 2017).
The success of the initial ENIGMA multi-site GWAS led to the
formation of over 50 collaborative ENIGMA Working Groups devel-
oping or using standardized protocols and studying a wide range of
neurodegenerative, neurodevelopmental and psychiatric disorders.
Working in parallel, and sharing standardized tools, the ENIGMA clini-
cal working groups published the largest neuroimaging studies of BD
(Hibar et al., 2016; Hibar et al., 2018), MDD (Schmaal et al., 2016;
Schmaal et al., 2017), schizophrenia (SCZ) (van Erp et al., 2016; van
Erp et al., 2018), obsessive compulsive disorder (OCD) (Boedhoe
et al., 2017; Boedhoe et al., 2018), attention deficit hyperactivity dis-
order (ADHD) (Hoogman et al., 2017, 2019), autism spectrum disorder
(ASD) (van Rooij et al., 2018), epilepsy (Whelan et al., 2018), sub-
stance use disorders (Mackey et al., 2019), PTSD (Dennis et al., 2019;
Logue et al., 2018) and 22q11.2 deletion syndrome (Ching
et al., 2020; Sun et al., 2018; Villalon-Reina et al., 2019). A more thor-
ough review of efforts across the ENIGMA Consortium may be found
in several recent articles (Bearden & Thompson, 2017; Thompson
et al., 2014; Thompson et al., 2020).
The ENIGMA Consortium offers a number of advantages com-
pared to previous smaller-scale neuroimaging studies. ENIGMA takes
advantage of existing data sets, reviving smaller samples that have
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often concluded data collection and primary publications. To date, the
ENIGMA consortium has incorporated over 70,000 scans from a
range of disorders and healthy individuals. ENIGMA currently includes
over 2,000 scientists from over 340 institutions, spanning 45 coun-
tries. By taking advantage of existing data and using parallel comput-
ing power across the world, ENIGMA has leveraged research
resources that benefit the wider research community at a relatively
modest study cost.
In the conventional, retrospective, literature-based meta-analysis,
summary statistics including effect sizes, confidence intervals and
standard errors are extracted from published studies (which have
often used different processing and analysis pipelines). These are then
combined mathematically to estimate an overall effect (e.g., regional
brain volume differences between BD and HC). A key strength of the
ENIGMA approach over more traditional meta-analyses is the imple-
mentation of standardized processing and analysis protocols to per-
form coordinated, prospective meta- and mega-analyses. These
protocols, which are publicly available (http://enigma.ini.usc.edu/
protocols), serve several purposes: 1) ENIGMA-standardized protocols
make it possible to efficiently and consistently extract measures from
MRI data and to perform robust quality assessment and statistical
modeling across tens to hundreds of international research centers
with varying neuroimaging expertise, 2) standardized processing and
analysis leads to more unbiased investigations of brain measures not
possible via traditional meta-analyses that combine published effect
sizes derived from varied processing and analysis protocols
(e.g., regions of interest combined with whole brain analyses, mass-
univariate combined with multivariate analyses, etc.), 3) pooling data
can overcome publication bias and boost statistical power by including
cohorts that may have been underpowered on their own to detect
effects on particular brain measures or associations with symptom
constructs, 4) harmonized protocols using standardized and publicly
available pipelines promote “open science” by increasing transparency
and encouraging replication, 5) it makes large-scale, post-hoc sub-
group explorations possible and lastly, 6) it allows for the direct com-
parison of large-scale, standardized data across ENIGMA Working
Groups to better understand common and distinct patterns that span
traditional diagnostic boundaries.
Importantly, and as previously mentioned, large-scale ENIGMA BD
Working Group efforts do not replace well-designed, smaller-scale neu-
roimaging studies, but rather complement one another. While the initial
ENIGMA studies were well powered to capture generalizable effects
across study samples, they can miss subtle, subtype-specific effects that
may be better captured by smaller well-controlled studies focusing on
particular subtypes or symptom patterns in BD, or with targeted deeper
phenotyping not economically feasible in large-scale studies. While the
large samples pooled through ENIGMA increase sensitivity to smaller
effect sizes, and are arguably more generalizable to the wider population,
potential lurking confounds or artifacts (e.g., head motion see Pardoe,
Hiess, & Kuzniecky, 2016; Yao et al., 2017) that may span independently
collected study samples must be carefully considered and modeled.
Lastly, the international coordination of ENIGMA studies requires
consensus and cooperation across a large number of centers worldwide.
In our experience, one of the more important steps to starting a
successful ENIGMA Working Group is to be pragmatic about the initial
studies carried out by the group. Focusing early efforts on a core set of
available variables and feasibly derived brain measures lowers the bar
for participation and helps to incorporate the greatest number of Work-
ing Group members. These early studies, while not necessarily applying
the most novel of brain metrics (e.g., volumes) or analysis models
(e.g., general linear models) are more feasible to accomplish while
simultaneously providing important consensus building findings in the
literature. The trust and infrastructure formed through these initial
pragmatic studies and publications helps build momentum toward more
ambitious projects using more advanced metrics (e.g., vertex-wise
measures, connectivity measures using graph theory, etc.) and more
advanced analyses (e.g., multivariate analysis, machine learning, struc-
tural covariance analysis, etc.).
2 | THE ENIGMA BIPOLAR DISORDER
WORKING GROUP
The ENIGMA Bipolar Disorder Working Group was formed in 2012 to
address some of the core limitations in BD research and foster collab-
orative discoveries using the wider ENIGMA Consortium research
model. The Working Group consists of an international team of over
150 clinicians, neuroscientists, bioengineers, and geneticists who pool
research resources from 20 countries and 55 institutions to conduct
large-scale neuroimaging studies of BD. The group has combined mul-
timodal neuroimaging data from 46 study cohorts which include
3,500 BD participants and  8,500 healthy controls, making it the
largest neuroimaging consortium effort to study BD (Figure 2). In the
following sections we discuss the Bipolar Disorder Working Group
and its contributions to understanding brain alterations in BD, includ-
ing guiding principles, current findings, ongoing projects and future
directions that aim to advance neurobiological research of BD and
other mental disorders.
2.1 | Goals and guiding principles
The primary research goals of the Bipolar Disorder Working Group
are to:
1. Make reliable discoveries that improve our understanding of the
pathophysiological mechanisms of BD.
2. Provide clinically relevant information to help improve BD nosol-
ogy, diagnosis, mechanistically-directed interventions and treat-
ment outcomes.
To accomplish these goals, the Bipolar Disorder Working Group
implemented ENIGMA-standardized protocols using open-source and
widely available processing platforms such as FreeSurfer (Fischl
et al., 2002) and FSL (Smith et al., 2006), as well as tools specifically
developed for large-scale, multisite projects (Figure 2).
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The BD Working Group operates under a set of simple guiding
principles (Figure 3). First, primary data sharing is not required to par-
ticipate in the working group; meta-analysis is always the encour-
aged/default analysis framework. This helps garner the greatest
number of participating samples and mitigates many data sharing chal-
lenges (Zugman et al., 2020). Working Group projects operate on an
“opt-in” principle, where members retain full ownership and control
over their data and are free to decide which project proposals they
wish to participate in. Furthermore, members can withdraw their data
or resources from a project at any time prior to publication.
New Working Group members are asked to sign a Memorandum
of Understanding (MOU) that has been standardized across the
ENIGMA Working Groups and sets a basic framework to protect par-
ticipating sites' data privacy, facilitate data sharing, encourage aca-
demic productivity, ensure appropriate publication credit and
authorship. It also provides a system to track and archive data,
analyses and publications related to the BD Working Group (http://
enigma.ini.usc.edu/ongoing/enigma-bipolar-working-group/ Figure 3).
The Working Group's scientific initiatives and basic policies are over-
seen by two Chairs, Dr. Ole A. Andreassen and Dr. Christopher R. K.
Ching, who are responsible for ensuring that working group studies
are carried out in accordance with appropriate ethical guidelines.
Working group members are provided an equal opportunity to
propose a project analysis plan. Analysis plans are developed and sub-
mitted in a standardized format with the help of the Working Group
Chairs and then presented to the full Working Group membership via
email and conference calls. Project leaders pitch their analysis plans to
the Working Group and each member reviews and decides whether
to contribute their data sample to the proposed projects (opt-in). Most
analysis plans earn widespread participation from the BD Working
Group members, resulting in large-scale studies that could not have
been accomplished independently.
F IGURE 2 (a) ENIGMA
Bipolar Disorder Working Group
sites across the world including
over 150 researchers from
20 countries and 55 institutions.
(b) Schematic of ENIGMA Bipolar
Disorder Working Group as it fits
into the larger ENIGMA
Consortium network. rsfMRI,
resting-state functional MRI;
tbfMRI, task-based functional
MRI; WM, white matter; DTI,
diffusion tensor imaging; MDD,
major depressive disorder; PTSD,
post-traumatic stress disorder;
OCD, obsessive–compulsive
disorder; CNVs, copy number
variants; Familial Risk, relatives of
individuals with psychiatric illness
(including bipolar disorder and
schizophrenia)
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The BD Working Group's initial goal was to demonstrate the
power and feasibility of large-scale, collaborative neuroimaging ana-
lyses by establishing minimal bureaucratic barriers for participation
and using standardized and publicly available processing and analysis
protocols (Figures 2 and 3). To date, the BD Working Group has publi-
shed five peer-reviewed studies and currently coordinates over
18 active and ongoing analysis projects led by Working Group mem-
bers from around the world.
3 | f PUBLISHED STUDIES
3.1 | Overview
The ENIGMA Bipolar Disorder Working Group has published five
peer-reviewed studies, each representing the largest neuroimaging
studies of their kind and helping to answer the question of which
brain structures are reliably associated with BD, its subtypes, and
other clinical measures such as illness duration, severity, genetic risk,
and common medications. Overall, these studies point to a diffuse
pattern of brain alterations including smaller subcortical volumes,
lower cortical thickness and altered white matter integrity in groups
of individuals with BD compared to healthy controls. Small to moder-
ate effect sizes are observed for ENIGMA-standardized brain mea-
sures, in line with prior reports from the BD literature. Common
medications such as lithium appear to have a normalizing effect on
gray and white matter structures, whereas other treatments such as
anticonvulsants appear to have the opposite effect. Standardized,
ROI-based cortical and subcortical brain measures were useful in pars-
ing differences between patients and non-affected relatives as well as
providing above chance predictive accuracy in classifying BD individ-
uals from controls using common machine learning techniques.
3.2 | Alterations to subcortical volumes and
associations with common pharmacological
treatments
The ENIGMA BD Working Group's first study was a meta-analysis of
subcortical gray matter brain volumes in 1,710 BD participants and
2,594 HC from 20 international sites, to identify effects of the disor-
der on regional morphometry, and rank structural brain metrics for
case–control differences. On average, higher bilateral ventricular vol-
umes and lower hippocampal, amygdala and thalamic volumes were
F IGURE 3 (a) Outline of the
ENIGMA BDWorking Group guiding
principles. (b) Flow diagram showing
working group logistics including
memorandum of understanding,
participation in and development of
new research proposals, data sharing,
etc. Ethics/IRB: The ENIGMA BD
Working group is experienced with
navigating international research
ethics and institutional review
boards, which may require additional
approval depending on project
specifics. More information on the
ENIGMA BDWorking group
including the Memorandum of
Understanding can be found online
(http://enigma.ini.usc.edu/ongoing/
enigma-bipolar-working-group/)
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detected in BD versus HC (Figure 4a) (Hibar et al., 2016). Importantly,
all case–control effect sizes were small to moderate and varied to
some degree across the 20 study samples. When combining the
effects across sites meta-analytically, clearer patterns emerged
(Figure 4b). The group differences may reflect either accelerated atro-
phy in BD with potential disease-related neuroprogression, chronic
effects of the illness, or medication. Alternatively, smaller volumes
may represent a potential risk factor for BD arising in early stages of
development. Importantly, prior meta-analyses were either unable to
detect case–control differences in amygdala volume or reported vari-
able effects (Altshuler et al., 2000; Chang et al., 2005).
No structural brain differences were detected between BD sub-
types (BD-I, BD-II and BD-NOS). Lithium treatment was associated
with larger thalamic volumes compared to non-treated individuals
F IGURE 4 Findings from Subcortical volumetric
abnormalities in bipolar disorder (Hibar et al., 2016).
(a) Cohen's d effect size estimates for subcortical
differences between individuals with BD versus
healthy controls (HC) using ENIGMA-standardized
FreeSurfer volumes. Statistical model accounts for
age, sex, and intracranial volume. Error bars indicate
mean effect size ± standard error of the mean.
Results passing study-wide significance threshold
are indicated by (*) including the amygdala which
showed a trending effect. (b) Forest plots displaying
the effect size estimates (adjusted Cohen's d) for
each of the 20 study sites in the comparison of
individuals with BD versus HC at each subcortical
structure along with the overall inverse variance-
weighted random-effects meta-analysis results
(RE Model)
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with BD. Compared to HC, individuals with BD not on lithium treat-
ment had smaller hippocampal and thalamic volumes, on average, and
larger lateral ventricles. Participants with BD taking anticonvulsants
had smaller hippocampal volumes compared to non-treated partici-
pants with BD. As discussed in the published study, these cross-
sectional results should be interpreted cautiously as medication status
is confounded to some extent with illness characteristics (such as
symptom severity). Furthermore, a simple binary coding (prescribed/
not prescribed) was used to determine medication status at the time
of scan. Current studies are investigating such medication factors as
treatment history, dose, and serum level, to better model interactions
between different pharmacological agents – polypharmacy is common
in BD – and their associated effects on brain structure (see Ongoing
and Future Studies section below and Supplemental Materials).
3.3 | Widespread cortical thickness alterations in
BD and associations with pharmacological treatment
Prior meta-analyses reported lower cortical thickness in the anterior
cingulate, paracingulate, superior temporal gyrus and prefrontal
regions associated with BD (Hanford, Nazarov, Hall, & Sassi, 2016;
Phillips & Swartz, 2014). Surface area findings have been more vari-
able – some larger studies detected no differences between BD and
HC (Rimol et al., 2010). In our second study, again the largest of its
kind, we focused on cortical structure (2,447 BD and 4,056 HC),
examining ENIGMA-standardized measures of cortical thickness and
surface area in an expanded ENIGMA BD sample including 28 interna-
tional sites (Hibar et al., 2018). Compared to controls, individuals with
BD exhibited a widespread pattern of thinner cortex (Figure 5a). Inter-
estingly, and in agreement with previous large sample studies, no
case–control differences were detected for cortical surface area. Lon-
ger illness duration was associated with a pattern of lower cortical
thickness but not with surface area alterations. As in the subcortical
study, no significant differences were detected between BD clinical
subtypes.
With regard to medication status, we found significantly higher
cortical thickness in participants with BD also taking lithium at the
time of scan, with the largest effects in the left paracentral gyrus (-
Figure 5b). Anticonvulsant treatment was associated with lower corti-
cal thickness, with the greatest effects in bilateral occipital gyri
(Figure 5C). Atypical “second-generation” antipsychotics were associ-
ated with lower cortical surface area in the rostral middle frontal
gyrus, whereas typical “first-generation” antipsychotics were associ-
ated with higher surface area in the left inferior parietal gyrus.
The cortical findings were largely in line with prior reports of thin-
ner frontal and temporal cortices in BD. Notably, regions with the
largest BD versus HC differences included the ventrolateral prefrontal
cortex, an area long implicated in BD pathophysiology. Important new
contributions include the observation of lower thickness in inferior
parietal, fusiform, and inferior temporal regions in adults with
BD. Structural deficits in these regions have been tied to disruptions
in sensorimotor integration (Caspers, Zilles, Laird, & Eickhoff, 2010)
and language (Vigneau et al., 2006), and may relate to altered emotion
perception and rapid mood changes in BD. Further studies are needed
to probe the functional relevance of regional cortical differences, and
how these effects may be interrelated (e.g., using structural covari-
ance analysis).
3.4 | Multi-site machine learning using brain MRI
to identify bipolar disorder
Differential diagnosis of BD remains a challenge, with mis-diagnosis
leading to delays in effective treatments. In an effort to improve diag-
nostic accuracy and, ultimately, personalize treatments, machine
learning can be used to find complex patterns in neuroimaging data
that predict diagnostic categories, or prognosis. In our first such study,
the Bipolar Working Group evaluated the capacity of a linear support
vector machine classifier to predict the diagnosis of BD using stan-
dardized cortical and subcortical ROI-based brain features from
853 individuals with BD and 2,167 HC acquired from 13 international
F IGURE 5 Findings from Cortical abnormalities in bipolar disorder: an MRI analysis of 6,503 individuals from the ENIGMA Bipolar Disorder
Working Group (Hibar et al., 2018). (a) A widespread pattern of thinner cortex in adult individuals with BD versus HC. Cohen's d effect sizes
plotted in regions passing correction for multiple comparisons. (b) Thicker cortex in adult individuals with BD taking lithium medication at time of
scan. (c) Thinner cortex in adult individuals with BD associated with anticonvulsant treatment at time of scan
12 CHING ET AL.
sites (Nunes et al., 2018). Under appropriate cross-validation proce-
dures, diagnosis of BD was classified with a sensitivity of 0.66 (95%
CI [0.63, 0.69]), a specificity of 0.65 (0.62, 0.67) and an area under the
receiver operating characteristic (ROC) curve of 0.71 (0.69, 0.74) (-
Figure 6). Informative features were in agreement with previous find-
ings, including the importance of hippocampus, amygdala (Hajek
et al., 2009, 2012), and cortical regions such as inferior frontal and
precentral gyri (Hibar et al., 2018).
When interpreting these results, we considered several issues.
BD and its clinical subtypes are difficult to diagnose leading to noise
in the target labels (i.e., derived brain measures). In addition, the illness
shows marked clinical and neurobiological heterogeneity. Many brain
alterations in BD are likely secondary to illness burden, presence or
absence of comorbid conditions (Hajek et al., 2014; Hajek, McIntyre, &
Alda, 2016), or treatments (Hibar et al., 2018; Van Gestel et al., 2019).
Since these secondary changes are not found in all participants and
reflect factors beyond the diagnosis, they cannot be used diagnosti-
cally. Last but not least, we worked with regional brain measures, not
raw/voxelwise data. This approach involves information loss in the
feature engineering process and using raw data could improve classifi-
cation accuracy. While clinician judgment for BD diagnosis and treat-
ment continues to outperform robust machine learning methods such
as those studied here, the accuracy observed in this study provides a
realistic and fair estimate of classification performance, which can be
achieved in a large, ecologically valid, multisite sample of individuals
with BD based on regional brain structure measures.
Our study provided further clues about the impact of data han-
dling on classification performance. Performing the machine learning
analyses on data pooled across the sites yielded a much better perfor-
mance than meta-analysis of site level results – the typical analytic
method in multisite collaborations. Thus, future multisite brain-
imaging machine learning studies should attempt to move toward
sharing of individual, raw data, not only site-level results. Developing
an ethico-legal framework to facilitate safe sharing of raw data is a
key and critical component of advancing medical machine learning
(Passos et al., 2019).
3.5 | Diffuse white matter alterations challenging
the existing models of bipolar disorder
Diffusion tensor imaging (DTI) studies of BD implicate widespread
white matter (WM) alterations within and beyond the fronto-limbic
regions that appear to precede emotional instability (Phillips &
Swartz, 2014). Limbic and non-limbic tract disruptions have been
reported (Canales-Rodriguez et al., 2014) but inconsistencies exist in
the literature and are likely due to the aforementioned research chal-
lenges. In our first DTI project, we aimed to identify generalizable
WM microstructural alterations with a standardized processing and
analysis framework (Jahanshad et al., 2013; Smith et al., 2006) to
study case–control differences, as well as associations with clinical
characteristics in BD. The project pooled data from 1,482 individuals
with BD and 1,551 HC from 26 research samples across 12 countries.
We used both meta- and mega-analyses to form the largest multicen-
ter DTI study of BD to date. Fractional anisotropy (FA) – a measure of
white matter directionality, coherence and integrity – was lower, on
average, in participants with BD across 29 out of 44 WM regions of
interest, with strongest effects in the corpus callosum and cingulum
(Figure 7). Higher FA was associated with later disorder onset and
shorter illness duration. Lithium treatment was associated with higher
FA, both globally and in a number of regions of interest including the
corona radiata, posterior thalamic radiation and internal capsule
(Favre et al., 2019). No significant FA alterations were detected
between BD subtypes (BD-I and BD-II diagnosis) or associated with
antidepressant use, illness severity (measured by number of mood epi-
sodes/duration of illness) or history of psychotic symptoms.
Unlike prior studies, we reported widespread FA alterations in BD –
a pattern similar to results from the ENIGMA Schizophrenia
F IGURE 6 Findings from Using structural MRI to identify bipolar disorders - 13 site machine learning study in 3020 individuals from the ENIGMA
Bipolar Disorders Working Group (Nunes et al., 2018). (a) Support vector machine (SVM) classifier performance trained on each site independently,
including mean and 95% confidence intervals for accuracy, area under the receiver operating curve (ROC-AUC), sensitivity, specificity, positive
predictive value (PPV) and negative predictive value (NPV). (b) Receiver operating curves from aggregate individual-level analysis with dashed line
indicating chance performance, blue line indicating mean ROC and gray lines indicating ROC curves from individual folds
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Working Group DTI study (Kelly et al., 2018). This suggests that a
global pattern of microstructural abnormalities may span both disor-
ders. Altered WM microstructure in the cingulum, a major limbic path-
way, is in agreement with prior reports of disrupted fronto-limbic
connectivity in BD (Mahon, Burdick, & Szeszko, 2010; Phillips &
Swartz, 2014). However, the role of the corpus callosum in BD is not
clear. WM alterations in individuals with BD with psychotic symptoms
have been reported (Sarrazin et al., 2014), but the role of the corpus
callosum in emotion processing or mood switching is not fully under-
stood (Linke et al., 2013; Wang et al., 2008). Lower corpus callosum
F IGURE 7 Findings fromWidespread white matter microstructural abnormalities in bipolar disorder: evidence from mega- and meta-analyses
across 3,033 individuals (Favre et al., 2019). Mega-analysis fractional anisotropy (FA) differences between BD and HC across 43 white matter
(WM) tracts and the whole-brain skeleton with R squared effect sizes and confidence intervals ranked by increasing order of magnitude for the
regions showing significant group differences. R, right; .L, left; CC, corpus callosum; BCC, body of the corpus callosum; GCC, genu of the corpus
callosum; CGC, cingulum; SCC, splenium of corpus callosum; FX, fornix; PTR, posterior thalamic radiation; EC, external capsule; ACR, anterior
corona radiata; SLF, superior longitudinal fasciculus; UNC, uncinate fasciculus; CR, corona radiata; SS, sagittal stratum; IFO, inferior fronto-
occipital fasciculus, SFO, superior fronto-occipital fasciculus; Average FA, average FA across full skeleton; PCR, posterior corona radiata; ALIC,
anterior limb of the internal capsule; FXST, fornix (cres) / stria terminalis
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FA was reported in the ENIGMA DTI meta-analysis of SCZ (Kelly
et al., 2018) and MDD (van Velzen et al., 2019), suggesting over-
lapping pathophysiology in psychosis and affective disorders
(Koshiyama et al., 2019). Further studies are needed to evaluate the
extent to which the corpus callosum might be differentially affected in
these related disorders. Preliminary data suggest that disruption of
interhemispheric connectivity is a disease marker rather than a vulner-
ability marker to BD (Chepenik et al., 2010; Linke et al., 2013). None-
theless, we identified extensive FA-related WM abnormalities, which
challenges current pathophysiological models of BD. Future models
should not be limited to fronto-limbic networks, and should consider
interhemispheric dysconnectivity as a feature of interest in BD.
An important limitations of the study was the focus on the most
commonly used DTI measure, FA, as opposed to including other scalar
measures such as mean, axial, and radial diffusivity derived from the
tensor model. The tensor, the most common method of modeling dif-
fusion MRI, while robust and widely used, has well documented limi-
tations such as inability to resolve crossing fibers – which are present
in a large proportion of brain white matter – or to disentangle the
intra- and extra-axonal compartments. As detailed below, ongoing
studies from the ENIGMA BD Working Group are currently applying
more advanced analysis techniques to model white matter. Further-
more, future BD research will likely benefit from new diffusion MRI
methods to model white matter tissue microstructure such as Neurite
Orientation Dispersion and Density Imaging (NODDI) (Zhang,
Schneider, Wheeler-Kingshott, & Alexander, 2012), which has been
used to highlight the impact of lithium on neurite density (Sarrazin
et al., 2019).
3.6 | Mapping familial risk to brain structure across
bipolar disorder and schizophrenia
Most neuroimaging studies to date have compared individuals with
BD to HC. The interpretation of case–control findings is complicated
by many of the aforementioned study limitations. An alternative
approach is to study first-degree family members (i.e., offspring, sib-
lings, parents or co-twins), as they are at higher risk for the disorder
but are otherwise healthy and unmedicated. As first-degree relatives
share, on average, half of the genes with their ill relative (except for
monozygotic co-twins who share all their genes), a family design pro-
vides a unique angle from which to study the effect of BD risk on
brain structure and function.
The ENIGMA-Relatives Working Group has taken a cross-disorder
approach to the study of BD and SCZ relatives, motivated by over-
lapping clinical symptoms, including delusions, hallucinations, mania,
depression and anxiety, as well as shared genetic and epidemiological
risk (Cross-Disorder Group of the Psychiatric Genomics Consortium,
2013; Kempf, Hussain, & Potash, 2005; Pearlson, 2015). While BD and
SCZ do show distinct symptom patterns and clinical course (Bora, 2015;
Correll, Penzner, Frederickson, et al., 2007; Murray & Sham, 2004), it
remains unclear whether they represent discrete entities shaped by dis-
tinct etiology and pathogenesis, or if they represent a spectrum of
mood-psychosis disorders. The ENIGMA-Relatives Working Group has
aimed to identify overlapping and distinct features of SZ and BD in first-
degree relatives of patients with these disorders.
In the largest study to date, standardized subcortical and global
brain measures were meta-analyzed across healthy first-degree
relatives of individuals with either BD (FDRs-BD) or SZ (FDRs-SZ)
(de Zwarte, Brouwer, Agartz, et al., 2019). A total of 6,008 participants
from 34 family cohorts, including 1,228 FDRs-SZ, 852 FDRs-BD, 2,246
HC, 1,016 participants with SZ and 666 with BD were included. The
main findings included: 1) FDRs-BD had larger average intracranial vol-
umes (ICV), whereas FDRs-SZ showed smaller thalamic volumes com-
pared with HC, 2) in FDRs-BD, ICV explained the larger brain volumes
in other regions, whereas in FDRs-SZ, brain volumes and thickness
effect sizes became significantly smaller compared to HC after statisti-
cal correction for ICV, 3) brain alterations differed between the relative
types, but no clear pattern was detected, and 4) findings were not con-
founded by other psychiatric diagnoses in the relatives (Figure 8).
When considering the finding of larger ICV in FDRs-BD but not
FDRs-SZ, as well as prior reports indicating a diverging pattern of ICV
volume for individuals with BD and SCZ (i.e., significantly smaller ICV
in SZ but not BD) (Hibar et al., 2016; van Erp et al., 2016), the
ENIGMA-Relatives Working Group recently investigated whether dif-
ferences in Intelligence Quotient (IQ) or educational attainment could
explain the findings in SZ and BD relatives. These most recent findings
are detailed in de Zwarte et al. from this issue.
4 | ONGOING AND FUTURE STUDIES
Building on these initial studies, the ENIGMA BD Working Group has
a growing list of ongoing projects to: (a) more finely map the initial
ROI-based findings of altered cortical/subcortical gray matter and
WM alterations in BD by using advanced, high-definition brain
morphometric features including vertex- or voxel-wise analysis, (b) improve
classification and individual-level prediction using data driven cluster-
ing/biotyping with more advanced machine learning techniques,
(c) investigate the impact of polygenic risk and gene expression
markers on large-scale standardized brain measures, (d) empower
future mega-analyses that allow more sophisticated designs than
meta-analyses, and (e) study how individual symptoms, functional
domains and risk factors map onto measures of brain structure and
function that cross classic diagnostic boundaries, revealing shared and
distinct brain markers of mental illness. Further details of the ongoing
Bipolar Disorder Working Group projects may be found in the Supple-
mental Materials.
4.1 | Finer mapping of BD-related brain variation
The ENIGMA Bipolar Working Group is currently applying advanced
techniques that model subcortical shape morphometry, hippocampal
subfield volumes, WM connectivity, neurometabolites, longitudinal
brain change and brain aging across thousands of individuals with BD
CHING ET AL. 15
and HC. These methods, now standardized for multisite studies, aim
to better characterize the spatial distribution of BD-related alterations
across the brain, track the longitudinal trajectory of such brain
changes across the course of illness, and determine the extent to
which those changes may interact with normal brain aging processes.
4.2 | Machine learning for better classification and
individual-level prediction
Most ENIGMA projects to date have applied relatively simple mass
univariate analysis methods when studying brain features. Combining
multiple imaging modalities will likely improve predictions of diagnosis
and prognosis. In addition to classical multivariate approaches, machine
learning models are being applied to neuroimaging data across a variety
of ENIGMA BD projects to predict diagnostic groups, treatment
response, and to characterize subtypes or clusters within groups of
individuals diagnosed with BD. Our initial efforts in the diagnostic clas-
sification of BD showed promise (Nunes et al., 2018), but accuracy is
likely to improve with the addition of functional neuroimaging mea-
sures (Han, De Berardis, Fornaro, & Kim, 2019; Phillips & Vieta, 2007),
as well as techniques that merge multimodal structural, functional,
vertex-wise metrics and in-depth clinical information. The BD Working
Group is tackling new challenges that arise when using higher-
dimensional data and when fitting complex models to provide improved
individual-level predictions.
4.3 | Large-scale direct comparisons of brain
measures across psychiatric disorders
A key question in psychiatric neuroimaging is the extent to which brain
variations are shared or differentiate major psychiatric disorders. Many
mental illnesses overlap in symptomatology, response to medication
F IGURE 8 Findings from The
association between familial risk
and brain abnormalities is disease-
specific: an ENIGMA–Relatives
study of schizophrenia and bipolar
disorder (de Zwarte et al., 2019).
Top: Cohen's d effect sizes
comparing BD and SCZ relatives
and healthy controls across global
brain measures. Bottom: global
effect sizes adjusted for total
intracranial volume (ICV).
*Nominally significant (p < .05
uncorrected); **q < .05 corrected
for multiple comparisons
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and underlying genetic risk. Examples include known intersections
between BD and MDD and SCZ (Pearlson, 2015; Rink, Pagel, Frank-
lin, & Baethge, 2016). Whether shared clinical features reflect similar
underlying brain structure and function is poorly understood. As
many clinically-focused ENIGMA Working Groups have completed
studies of cortical and subcortical structure, direct comparison of
brain measures for tens of thousands of participants is now possible.
The resulting data set represents the largest collection of psychiatric
neuroimaging data ever amassed using standardized processing tech-
niques, and the largest samples of BD, MDD, and SCZ neuroimaging
data ever analyzed.
The initial case–control studies from the ENIGMA clinical working
groups (Figure 9) suggest overlapping and distinct patterns of brain
alterations across disorders. Notably, ENIGMA SCZ case–control cor-
tical effects were more widespread and greater in magnitude than
those found in BD and MDD. In line with prior hypotheses regarding
underlying biological correlates of BD versus MDD, frontal lobe sys-
tems showed greater deficits in ENIGMA BD cases, whereas limbic
regions tended to show greater deficits in ENIGMA MDD cases.
Smaller hippocampal volume is another common finding across publi-
shed ENIGMA psychiatric studies. Preliminary analyses, correlating
effect sizes across published ENIGMA psychiatric working group stud-
ies, indicate significant correlations between cortical and subcortical
MRI alterations across disorders, which may be partially explained by
common underlying genetic markers (Ching et al., 2020).
For pragmatic reasons, and to help incorporate the greatest
number of Working Group sites in initial analyses, the first ENIGMA
BD Working Group studies tended to include a limited number of
essential variables such as age, sex, diagnosis, age of illness onset,
binary (yes/no) medication status at the time of scan, and simple
severity measures. The next phase of ENIGMA cross-disorder ana-
lyses is tackling the challenges of deeper phenotyping and the het-
erogeneity across samples. The ENIGMA BD Working Group is
collecting in-depth clinical and demographic information in a har-
monized effort with the ENIGMA SCZ and MDD Working Groups
from over 200 data sets. Metrics of interest include education,
socioeconomic status, IQ, body mass index, number of psychiatric
hospitalizations, number of episodes (depressive, manic, psychotic),
substance use disorder, comorbid psychiatric disorders, current/
lifetime medication treatment, medication dose, medication serum
level, and detailed behavioral/symptom information. These mea-
sures will provide the basis for comparisons not dependent on clas-
sic diagnostic categorizations. Work is underway to find
overlapping scales and measures and to resolve clinical/behavioral
measurement harmonization and empower analyses more in line
with the Research Domain Criteria (RDoC) framework (Insel, 2014).
Clinical information will also allow for analyses such as network
modeling of individual symptoms (Borsboom & Cramer, 2013) and
thus a more detailed characterization than traditional diagnostic
categories. Such modeling can also be done in combination with
F IGURE 9 Cortical thickness differences across ENIGMA working groups. Cohen's d effect sizes comparing cases versus healthy controls
(HC) plotted across 34 bilateral cortical ROIs from ENIGMA-standardized FreeSurfer protocol (http://enigma.ini.usc.edu/protocols/). Warmer
colors indicate lower thickness in cases/patients, whereas cooler colors indicate greater thickness in cases/patients versus HC. Results derived
from published ENIGMA studies: bipolar disorder (N = 4,419, 28 sites, Hibar et al., 2018), major depressive disorder (N = 10,105, 15 sites,
Schmaal et al., 2017), schizophrenia (N = 9,572, 39 sites, van Erp et al., 2018), attention deficit hyperactivity disorder (ADHD N = 4,180, 36 sites,
Hoogman et al., 2019), obsessive–compulsive disorder (OCD N = 3,665, 27 sites, Boedhoe et al., 2018) and autism spectrum disorder (ASD
N = 3,222, 49 sites, van Rooij et al., 2018)
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brain and other biological measures, as in recent studies of MDD
(Fried et al., 2019; Hilland et al., 2019).
Advanced supervised and unsupervised machine learning tech-
niques are being applied to examine the extent to which BD, MDD
and SCZ can be discriminated on the basis of ENIGMA-standardized
brain measures. Of particular interest is whether multivariate, machine
learning techniques can discriminate between alternative patient
groupings and cluster individuals according to duration of illness,
symptom severity, presence of depressive and/or psychotic symp-
toms, substance use, treatment response and other characteristics
that might improve individual-level predictive accuracy.
4.4 | Linking genetic risk and gene expression to
brain alterations across psychiatric disorders
The ENIGMA bipolar disorder working group is uniquely positioned to
study how genetic risk loci affect brain structure and function. In col-
laboration with the Psychiatric Genomics Consortium Working Group
on Bipolar Disorders (PGC-BD), we are deriving polygenic risk scores
(PRS) across participating ENIGMA BD Working Group sites using
recent discoveries from the PGC-BD group (Bipolar Disorder and
Schizophrenia Working Group of the PGC, 2018; Stahl et al., 2019).
The ENIGMA PRS protocol is freely available online (http://enigma.
ini.usc.edu/protocols/) and is empowering projects to map BD-PRS
vulnerability across brain structures, as well as genetic risk for
other psychiatric disorders. This effort aims to both identify brain
regions at risk in BD as well as construct overlapping genotype–
phenotype risk maps across common psychiatric disorders, which
may reveal more mechanistic models of shared and unique disease
processes.
A key challenge in neuroimaging is bridging the gap between
in vivo MRI and ex vivo histology (Paus, 2018). To address this, several
ENIGMA working groups applied a “virtual histology” approach, where
profiles of structural brain metrics, namely group differences in cortical
thickness, are related to gradients in cell-specific gene expression using
data from the Allen Human Brain Atlas (Hawrylycz et al., 2012; Patel
et al., 2018; Shin et al., 2017). Inter-regional profiles of group differ-
ences in cortical thickness have been generated meta-analytically
across over 12,000 cases and 15,000 HC from the ENIGMA BD, ASD,
ADHD, OCD, MDD and SCZ Working Groups. Associations of a given
cell type with a profile of group differences in cortical thickness are cor-
related with cell-specific gene expression to better characterize shared
and unique gene expression potentially driving cortical alterations
across these major neuropsychiatric disorders.
5 | FUTURE PERSPECTIVES:
REPLICATION, BIG DATA AND SHIFTING THE
PARADIGM IN PSYCHIATRIC RESEARCH
BD is a complex illness where individual factors confer a small propor-
tion of the overall risk. The ENIGMA Bipolar Disorder Working Group
is focused on applying innovative, big data approaches to provide reli-
able new discoveries on the biological underpinnings of BD, and to
generate clinically relevant findings to improve diagnosis and
treatment.
The current psychiatric research paradigm, which seeks markers
that link high-level, behavioral-based diagnostic labels to underlying
biology, is slowly changing. Neuroimaging may not provide the larger
BD-related effect sizes once proposed by the “endophenotypes”
hypothesis, but the combination of large-scale neuroimaging data sets
has led to a better understanding of the brain regions that mediate the
link between genetic risk and the behavioral manifestations of BD.
Several limitations to the ENIGMA Bipolar Disorder Working
Group approach must be discussed. First, Working Group sites col-
lected data independently and used a range of tools and methods that
can differ with respect to MRI scanner (hardware and software),
biospecimen collection, behavioral assessment, study inclusion/exclu-
sion criteria and overall data quality. While ENIGMA studies deploy
standardized processing and analysis techniques that reduce the vari-
ance across site measurements, true data harmonization is only possi-
ble through prospective data collection. Second, the ENIGMA Bipolar
Working Group consists of fairly Eurocentric data samples. Future
efforts must be made to incorporate additional data sets from all cor-
ners of the world to garner an even more ecologically valid sample of
BD phenotypes. Third, early ENIGMA studies initially deploy prag-
matic analysis plans, using only the most common measures across
Working Group sites (e.g., binary medication status at time of scan,
primary diagnosis, etc.) and applying mass univariate analysis methods
(e.g., BD case vs. HC differences assessed by multiple linear regres-
sion). While this approach has led to the incorporation of many stan-
dardized data sets and has helped to clarify basic brain structure
alterations in BD, group-level results only allow for broad generaliza-
tions about individuals with BD and have limited clinical applications
when assessing and treating individual patients. Fourth, all of the pub-
lished studies from the Bipolar Disorder Working Group have so far
used a cross-sectional design. There is increasing evidence that BD is
a neuroprogressive disorder – our own results indicate associations
between duration of illness and brain structure (Favre et al., 2019;
Hibar et al., 2018) – which requires a longitudinal design that may
inform better clinical staging and treatment of the illness (Salagre
et al., 2018). Longitudinal studies that include participants with vary-
ing ages of onset may also help to address whether brain alterations
are indeed inherent markers of BD or are a consequence of factors
associated with illness duration. Longitudinal studies in the context of
therapeutic trials will also clarify the effect of interventions on the
brain, although there are many challenges in integrating such data
across sites.
With these limitations in mind, the ENIGMA Bipolar Disorder
Working Group has several future research goals:
1. Incorporate advanced and standardized multimodal measures. Com-
bining multimodal biological measures that encompass genetic,
neurochemical, neuroimaging and behavioral factors will likely lead
to more clinically relevant biomarkers for improved patient-level
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predictions and a better understanding of BD pathophysiology.
Innovative standardized protocols now being applied in the
ENIGMA Bipolar Disorder Working Group include white matter
connectivity, resting and task-based fMRI, spectroscopy, vertex-
wise shape morphometry, longitudinal brain change and deeper
clinical and behavioral phenotyping.
2. Advance novel, big data techniques. We are currently applying
advanced machine learning models to predict classic diagnostic
groups, as well as potential patient subgroup stratification along
behavioral and treatment measures. New multivariate GWAS
methods are helping to reveal more of the hidden genetic risk for
BD (e.g., the MOSTest, see van der Meer et al., 2019) and are
being applied through our collaboration with the PGC. These
genetic findings further empower the ENIGMA Bipolar Working
Group's ability to map genetic risk to brain structure and function.
3. Cross-disorder studies. Large-scale, transdiagnostic efforts such as
those being carried out between the ENIGMA BD, MDD, and SCZ
working groups will help us understand the common and unique
neurobiological factors underlying mental illnesses.
4. Hypothesis-driven prospective analyses. Our international collabora-
tions are driving future prospective studies with more harmonized
data collection. Lessons learned from ongoing gross neuroimaging
analyses inform future micro- and ultrascale studies of cellular
morphometry, distribution, and synaptic structure and function,
which may provide a more mechanistic link between genes and
behavior in BD (Le & Stein, 2019). A centrally coordinated, long-
term study of a large cohort of individuals with BD across the
lifespan is desperately needed. Such a study, collecting neuroimag-
ing, cellular, molecular and other deeper phenotyping measures
akin to studies such as UK Biobank and other longitudinal cohorts
(McInnis & Greden, 2016; Miller et al., 2016; Yatham, Kauer-San-
t'Anna, Bond, Lam, & Torres, 2009), and integrated with pharmaco-
logical and behavioral treatment interventions would provide an
ambitious path forward to addressing many of the key challenges
facing BD research.
The ENIGMA BD Working Group has demonstrated that large-
scale, international collaborations can empower replicable and gener-
alizable studies of BD. To the goal of more open and reproducible sci-
ence, the ENIGMA Consortium is building an Organic Data Science
(ODS) tool to facilitate complex and dynamic working group activities
via a systematic information system. Based on Semantic MediaWiki,
ENIGMA-ODS provides cross-working group data queries and project
tracking to improve study reproducibility and help to overcome bar-
riers to efficiency that are inherent in large-scale projects (Jahanshad
et al., 2015). Furthermore, the use of publicly available and standard-
ized processing and analysis protocols may empower future “living
studies” or continuously updated research findings (e.g., associations
with subcortical volume and psychotic symptoms), with semi-
automated addition of future cohorts to an ever-increasing ENIGMA-
standardized research sample.
Engaging patients is vital to ensure that biomedical research, and
the subsequent interventions and tools, meet the needs of individuals
living with BD. The Milken Institute and the Depression and Bipolar
Support Alliance recently surveyed over 6,000 individuals living with
MDD and BD to better understand research priorities from individuals
living with these illnesses (Altimus, 2019). Survey respondents identi-
fied the ability to be independent or act according to one's own will as
the top wellness priority, while only 20% of individuals identified the
lack of symptoms of acute MDD or BD as a measure of wellness. Fur-
thermore, 54% of respondents reported experiencing both MDD and
BD symptoms, contrary to a discrete diagnosis given by clinicians.
These discrepancies in both wellness priorities and manifestation of
the disorder demonstrate that the most pressing needs of individuals
with BD may not align with the goals of researchers. Moving forward,
the ENIGMA BD working group aims to actively engage user groups
to help focus our research goals and engage new participants in future
studies.
The ENIGMA BD Working Group is actively recruiting new
research collaborators and the infrastructure allows for new groups to
be efficiently incorporated into ongoing and future analyses. Groups
interested in joining, contributing data, and starting their own research
proposal using the largest neuroimaging data set in BD research are
encouraged to contact the Working Group Chairs.
The ENIGMA Bipolar Working Group will continue to be
guided by the collective expertise of a strong network of neurosci-
entists, psychiatrists, data scientists, bioengineers and geneticists
(Guglielmi, 2018). Big data consortia efforts offer the opportunity to
work cohesively on related research questions, bringing diverse infor-
mation to bear on neuroscientific problems, and will continue to pro-
vide valuable discoveries, revealing consensus findings and informing
future hypothesis-driven studies of BD and other neuropsychiatric
disorders.
All images taken from original publications are approved for
reprint under creative commons licensing.
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ENDNOTE
1 A biomarker is an objective genetic, biomolecular or morphological indi-
cator of a normal/pathological process or biological response to thera-
peutic intervention used for diagnosis or prognosis (Atkinson
et al., 2001; Venkatasubramanian & Keshavan, 2016).
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